GATA3 as a master regulator and therapeutic target in ovarian high-grade serous carcinoma stem cells

Hsiang Ju Chen, Rui Lan Huang, Phui Ly Liew, Po Hsuan Su, Lin Yu Chen, Yu Chun Weng, Cheng Chang Chang, Yu Chi Wang, Michael Wing Yan Chan, Hung Cheng Lai

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Ovarian high-grade serous carcinoma (HGSC) is the most lethal gynecological malignancy. Prevailing evidences suggest that drug resistance and recurrence of ovarian HGSC are caused by the presence of cancer stem cells. Therefore, targeting cancer stems is appealing, however, all attempts to date, have failed. To circumvent this limit, we analyzed differential transcriptomes at early differentiation of ovarian HGSC stem cells and identified the developmental transcription factor GATA3 as highly expressed in stem, compared to progenitor cells. GATA3 expression associates with poor prognosis of ovarian HGSC patients, and was found to recruit the histone H3, lysine 27 (H3K27) demethylase, UTX, activate stemness markers, and promote stem-like phenotypes in ovarian HGSC cell lines. Targeting UTX by its inhibitor, GSKJ4, impeded GATA3-driven stemness phenotypes, and enhanced apoptosis of GATA3-expressing cancer cells. Combinations of gemcitabine or paclitaxel with GSKJ4, resulted in a synergistic cytotoxic effect. Our findings provide evidence for a new role for GATA3 in ovarian HGSC stemness, and demonstrate that GATA3 may serve as a biomarker for precision epigenetic therapy in the future.

Original languageEnglish
JournalInternational Journal of Cancer
DOIs
Publication statusAccepted/In press - Jan 1 2018

Fingerprint

Stem Cells
Carcinoma
gemcitabine
GATA3 Transcription Factor
Therapeutics
Phenotype
Neoplasms
Neoplastic Stem Cells
Paclitaxel
Transcriptome
Drug Resistance
Epigenomics
Histones
Lysine
Biomarkers
Apoptosis
Recurrence
Cell Line

Keywords

  • cancer stem cells
  • GATA3
  • GSKJ4
  • ovarian cancer
  • UTX

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

GATA3 as a master regulator and therapeutic target in ovarian high-grade serous carcinoma stem cells. / Chen, Hsiang Ju; Huang, Rui Lan; Liew, Phui Ly; Su, Po Hsuan; Chen, Lin Yu; Weng, Yu Chun; Chang, Cheng Chang; Wang, Yu Chi; Chan, Michael Wing Yan; Lai, Hung Cheng.

In: International Journal of Cancer, 01.01.2018.

Research output: Contribution to journalArticle

Chen, Hsiang Ju ; Huang, Rui Lan ; Liew, Phui Ly ; Su, Po Hsuan ; Chen, Lin Yu ; Weng, Yu Chun ; Chang, Cheng Chang ; Wang, Yu Chi ; Chan, Michael Wing Yan ; Lai, Hung Cheng. / GATA3 as a master regulator and therapeutic target in ovarian high-grade serous carcinoma stem cells. In: International Journal of Cancer. 2018.
@article{fa39c5b85e054ef98f8ca4015e3cd2f7,
title = "GATA3 as a master regulator and therapeutic target in ovarian high-grade serous carcinoma stem cells",
abstract = "Ovarian high-grade serous carcinoma (HGSC) is the most lethal gynecological malignancy. Prevailing evidences suggest that drug resistance and recurrence of ovarian HGSC are caused by the presence of cancer stem cells. Therefore, targeting cancer stems is appealing, however, all attempts to date, have failed. To circumvent this limit, we analyzed differential transcriptomes at early differentiation of ovarian HGSC stem cells and identified the developmental transcription factor GATA3 as highly expressed in stem, compared to progenitor cells. GATA3 expression associates with poor prognosis of ovarian HGSC patients, and was found to recruit the histone H3, lysine 27 (H3K27) demethylase, UTX, activate stemness markers, and promote stem-like phenotypes in ovarian HGSC cell lines. Targeting UTX by its inhibitor, GSKJ4, impeded GATA3-driven stemness phenotypes, and enhanced apoptosis of GATA3-expressing cancer cells. Combinations of gemcitabine or paclitaxel with GSKJ4, resulted in a synergistic cytotoxic effect. Our findings provide evidence for a new role for GATA3 in ovarian HGSC stemness, and demonstrate that GATA3 may serve as a biomarker for precision epigenetic therapy in the future.",
keywords = "cancer stem cells, GATA3, GSKJ4, ovarian cancer, UTX",
author = "Chen, {Hsiang Ju} and Huang, {Rui Lan} and Liew, {Phui Ly} and Su, {Po Hsuan} and Chen, {Lin Yu} and Weng, {Yu Chun} and Chang, {Cheng Chang} and Wang, {Yu Chi} and Chan, {Michael Wing Yan} and Lai, {Hung Cheng}",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/ijc.31750",
language = "English",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - GATA3 as a master regulator and therapeutic target in ovarian high-grade serous carcinoma stem cells

AU - Chen, Hsiang Ju

AU - Huang, Rui Lan

AU - Liew, Phui Ly

AU - Su, Po Hsuan

AU - Chen, Lin Yu

AU - Weng, Yu Chun

AU - Chang, Cheng Chang

AU - Wang, Yu Chi

AU - Chan, Michael Wing Yan

AU - Lai, Hung Cheng

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Ovarian high-grade serous carcinoma (HGSC) is the most lethal gynecological malignancy. Prevailing evidences suggest that drug resistance and recurrence of ovarian HGSC are caused by the presence of cancer stem cells. Therefore, targeting cancer stems is appealing, however, all attempts to date, have failed. To circumvent this limit, we analyzed differential transcriptomes at early differentiation of ovarian HGSC stem cells and identified the developmental transcription factor GATA3 as highly expressed in stem, compared to progenitor cells. GATA3 expression associates with poor prognosis of ovarian HGSC patients, and was found to recruit the histone H3, lysine 27 (H3K27) demethylase, UTX, activate stemness markers, and promote stem-like phenotypes in ovarian HGSC cell lines. Targeting UTX by its inhibitor, GSKJ4, impeded GATA3-driven stemness phenotypes, and enhanced apoptosis of GATA3-expressing cancer cells. Combinations of gemcitabine or paclitaxel with GSKJ4, resulted in a synergistic cytotoxic effect. Our findings provide evidence for a new role for GATA3 in ovarian HGSC stemness, and demonstrate that GATA3 may serve as a biomarker for precision epigenetic therapy in the future.

AB - Ovarian high-grade serous carcinoma (HGSC) is the most lethal gynecological malignancy. Prevailing evidences suggest that drug resistance and recurrence of ovarian HGSC are caused by the presence of cancer stem cells. Therefore, targeting cancer stems is appealing, however, all attempts to date, have failed. To circumvent this limit, we analyzed differential transcriptomes at early differentiation of ovarian HGSC stem cells and identified the developmental transcription factor GATA3 as highly expressed in stem, compared to progenitor cells. GATA3 expression associates with poor prognosis of ovarian HGSC patients, and was found to recruit the histone H3, lysine 27 (H3K27) demethylase, UTX, activate stemness markers, and promote stem-like phenotypes in ovarian HGSC cell lines. Targeting UTX by its inhibitor, GSKJ4, impeded GATA3-driven stemness phenotypes, and enhanced apoptosis of GATA3-expressing cancer cells. Combinations of gemcitabine or paclitaxel with GSKJ4, resulted in a synergistic cytotoxic effect. Our findings provide evidence for a new role for GATA3 in ovarian HGSC stemness, and demonstrate that GATA3 may serve as a biomarker for precision epigenetic therapy in the future.

KW - cancer stem cells

KW - GATA3

KW - GSKJ4

KW - ovarian cancer

KW - UTX

UR - http://www.scopus.com/inward/record.url?scp=85054395443&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054395443&partnerID=8YFLogxK

U2 - 10.1002/ijc.31750

DO - 10.1002/ijc.31750

M3 - Article

AN - SCOPUS:85054395443

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

ER -